{
	"@context": {
		"rdf": "http://www.w3.org/1999/02/22-rdf-syntax-ns#",
		"dct": "http://purl.org/dc/terms/",
		"owl": "http://www.w3.org/2002/07/owl#",
		"xsd": "http://www.w3.org/2001/XMLSchema#",
		"rdfs": "http://www.w3.org/2000/01/rdf-schema#",
		"@vocab": "http://ld.nice.org.uk/ns/bnf#",
		"bnf": "http://ld.nice.org.uk/ns/bnf/",
		"nicebnf": "http://ld.nice.org.uk/ns/bnf#",
		"route": "http://ld.nice.org.uk/ns/bnf/Route#",
		"patientGroup": "http://ld.nice.org.uk/ns/bnf/PatientGroup#",
		"indication": "http://ld.nice.org.uk/ns/bnf/Indication#",
		"sideEffect": "http://ld.nice.org.uk/ns/bnf/SideEffect#",
		"classification": "http://ld.nice.org.uk/ns/bnf/Classification#",
		"isLinkedFrom": {
			"@container": "@set"
		},
		"hasInteraction": {
			"@container": "@set"
		},
		"hasMessage": {
			"@container": "@set"
		},
		"hasInteractionList": {
			"@container": "@set"
		},
		"isInteractionListOf": {
			"@container": "@set"
		}
	},
	"@graph": [
		{
			"@id": "http://bnf.nice.org.uk/interaction/rifabutin-2",
			"@type": "InteractionList",
			"hasInteraction": [
				{
					"@id": "http://bnf.nice.org.uk/interaction/rifabutin-2#bnf_i1643858010452",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/rifabutin-2#bnf_i1643858010452_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"rifabutin\" outputclass=\"int-heading-drug\">Rifabutin</ph> <ph outputclass=\"int-effectQualifier\">might</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the anticoagulant effect of</ph> <ph otherprops=\"acenocoumarol\" outputclass=\"int-drug\">acenocoumarol</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Rifabutin   might   decrease   the anticoagulant effect of   acenocoumarol .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "1",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Acenocoumarol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/rifabutin-2#bnf_i1643858010453",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/rifabutin-2#bnf_i1643858010453_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"atazanavir\" outputclass=\"int-drug\">Atazanavir</ph> <ph outputclass=\"int-substanceQualifier\">boosted with ritonavir</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"rifabutin\" outputclass=\"int-heading-drug\">rifabutin</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor and adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Atazanavir   boosted with ritonavir   increases   the exposure to   rifabutin .  Manufacturer advises monitor and adjust dose .    \n\n"
						}
					],
					"hasOrder": "2",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Atazanavir</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/rifabutin-2#bnf_i1643858010454",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/rifabutin-2#bnf_i1643858010454_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"rifabutin\" outputclass=\"int-heading-drug\">Rifabutin</ph> <ph outputclass=\"int-magnitude\">slightly</ph> <ph outputclass=\"int-effect\">decreases</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"atovaquone\" outputclass=\"int-drug\">atovaquone</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Rifabutin   slightly   decreases   the exposure to   atovaquone .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "3",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Atovaquone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/rifabutin-2#bnf_i1643858010455",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/rifabutin-2#bnf_i1643858010455_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"rifabutin\" outputclass=\"int-heading-drug\">Rifabutin</ph> <ph outputclass=\"int-effectQualifier\">has been reported to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">neutropenia when given with</ph> <ph otherprops=\"azithromycin\" outputclass=\"int-drug\">azithromycin</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Rifabutin   has been reported to   cause   neutropenia when given with   azithromycin .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "4",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Azithromycin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/rifabutin-2#bnf_i1643858010456",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/rifabutin-2#bnf_i1643858010456_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"rifabutin\" outputclass=\"int-heading-drug\">Rifabutin</ph> <ph outputclass=\"int-magnitude\">slightly</ph> <ph outputclass=\"int-effect\">decreases</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"bictegravir\" outputclass=\"int-drug\">bictegravir</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Rifabutin   slightly   decreases   the exposure to   bictegravir .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "5",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bictegravir</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/rifabutin-2#bnf_i1643858010457",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/rifabutin-2#bnf_i1643858010457_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"rifabutin\" outputclass=\"int-heading-drug\">Rifabutin</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"cabazitaxel\" outputclass=\"int-drug\">cabazitaxel</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Rifabutin   is predicted to   decrease   the exposure to   cabazitaxel .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "6",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cabazitaxel</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/rifabutin-2#bnf_i1643858010458",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/rifabutin-2#bnf_i1643858010458_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"rifabutin\" outputclass=\"int-heading-drug\">Rifabutin</ph> <ph outputclass=\"int-effectQualifier\">has been reported to</ph> <ph outputclass=\"int-effect\">cause a small decrease in</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"cabotegravir\" outputclass=\"int-drug\">cabotegravir</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid intramuscular <ph otherprops=\"cabotegravir\" outputclass=\"int-drug\"><xref format=\"dita\" href=\"drug/cabotegravir.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP223423\">cabotegravir</xref></ph></ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Rifabutin   has been reported to   cause a small decrease in   the exposure to   cabotegravir .  Manufacturer advises avoid intramuscular  cabotegravir .    \n\n"
						}
					],
					"hasOrder": "7",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cabotegravir</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/rifabutin-2#bnf_i1643858010459",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/rifabutin-2#bnf_i1643858010459_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"rifabutin\" outputclass=\"int-heading-drug\">Rifabutin</ph> <ph outputclass=\"int-effect\">decreases</ph> <ph outputclass=\"int-parameter\">the concentration of</ph> <ph otherprops=\"clarithromycin\" outputclass=\"int-drug\">clarithromycin</ph> and <ph otherprops=\"clarithromycin\" outputclass=\"int-drug\">clarithromycin</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the concentration of</ph> <ph otherprops=\"rifabutin\" outputclass=\"int-heading-drug\">rifabutin</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor and adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Rifabutin   decreases   the concentration of   clarithromycin  and  clarithromycin   increases   the concentration of   rifabutin .  Manufacturer advises monitor and adjust dose .    \n\n"
						}
					],
					"hasOrder": "8",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Clarithromycin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/rifabutin-2#bnf_i1643858010460",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/rifabutin-2#bnf_i1643858010460_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"rifabutin\" outputclass=\"int-heading-drug\">Rifabutin</ph> <ph outputclass=\"int-effect\">decreases</ph> <ph outputclass=\"int-parameter\">the concentration of</ph> <ph otherprops=\"cobicistat\" outputclass=\"int-drug\">cobicistat</ph> and <ph otherprops=\"cobicistat\" outputclass=\"int-drug\">cobicistat</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"rifabutin\" outputclass=\"int-heading-drug\">rifabutin</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid or adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Rifabutin   decreases   the concentration of   cobicistat  and  cobicistat   increases   the exposure to   rifabutin .  Manufacturer advises avoid or adjust dose .    \n\n"
						}
					],
					"hasOrder": "9",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cobicistat</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/rifabutin-2#bnf_i1643858010461",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/rifabutin-2#bnf_i1643858010461_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"rifabutin\" outputclass=\"int-heading-drug\">Rifabutin</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the efficacy of</ph> <ph otherprops=\"combined hormonal contraceptives\" outputclass=\"int-drug\">combined hormonal contraceptives</ph>. <ph outputclass=\"int-action\">For FSRH guidance, see <xref format=\"dita\" href=\"treatment-summary/contraceptives-interactions.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP92512\">Contraceptives, interactions</xref></ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Rifabutin   is predicted to   decrease   the efficacy of   combined hormonal contraceptives .  For FSRH guidance, see  Contraceptives, interactions .    \n\n"
						}
					],
					"hasOrder": "10",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Combined hormonal contraceptives</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/rifabutin-2#bnf_i1643858010462",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/rifabutin-2#bnf_i1643858010462_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"rifabutin\" outputclass=\"int-heading-drug\">Rifabutin</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the efficacy of</ph> <ph otherprops=\"cyproterone\" outputclass=\"int-drug\">cyproterone</ph> <ph outputclass=\"int-substanceQualifier\">with ethinylestradiol (co-cyprindiol)</ph>. <ph outputclass=\"int-action\">Manufacturer advises use alternative methods during treatment with, and for 28 days after, the enzyme inducing drug is stopped</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Rifabutin   is predicted to   decrease   the efficacy of   cyproterone   with ethinylestradiol (co-cyprindiol) .  Manufacturer advises use alternative methods during treatment with, and for 28 days after, the enzyme inducing drug is stopped .    \n\n"
						}
					],
					"hasOrder": "11",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cyproterone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/rifabutin-2#bnf_i1643858010463",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/rifabutin-2#bnf_i1643858010463_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"rifabutin\" outputclass=\"int-heading-drug\">Rifabutin</ph> <ph outputclass=\"int-effect\">decreases</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"dapsone\" outputclass=\"int-drug\">dapsone</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Rifabutin   decreases   the exposure to   dapsone .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "12",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dapsone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/rifabutin-2#bnf_i1643858010464",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/rifabutin-2#bnf_i1643858010464_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"darunavir\" outputclass=\"int-drug\">Darunavir</ph> <ph outputclass=\"int-substanceQualifier\">boosted with ritonavir</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"rifabutin\" outputclass=\"int-heading-drug\">rifabutin</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor and adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Darunavir   boosted with ritonavir   increases   the exposure to   rifabutin .  Manufacturer advises monitor and adjust dose .    \n\n"
						}
					],
					"hasOrder": "13",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Darunavir</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/rifabutin-2#bnf_i1643858010465",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/rifabutin-2#bnf_i1643858010465_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"rifabutin\" outputclass=\"int-heading-drug\">Rifabutin</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the efficacy of</ph> <ph otherprops=\"desogestrel\" outputclass=\"int-drug\">desogestrel</ph>. <ph outputclass=\"int-action\">For FSRH guidance, see <xref format=\"dita\" href=\"treatment-summary/contraceptives-interactions.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP92512\">Contraceptives, interactions</xref></ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Rifabutin   is predicted to   decrease   the efficacy of   desogestrel .  For FSRH guidance, see  Contraceptives, interactions .    \n\n"
						}
					],
					"hasOrder": "14",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Desogestrel</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/rifabutin-2#bnf_i1643858010466",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/rifabutin-2#bnf_i1643858010466_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"rifabutin\" outputclass=\"int-heading-drug\">Rifabutin</ph> <ph outputclass=\"int-magnitude\">moderately</ph> <ph outputclass=\"int-effect\">decreases</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"doravirine\" outputclass=\"int-drug\">doravirine</ph>. <ph outputclass=\"int-action\">Manufacturer advises adjust <xref format=\"dita\" href=\"drug/doravirine.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP219163\">doravirine</xref> or <xref format=\"dita\" href=\"drug/lamivudine-with-tenofovir-disoproxil-and-doravirine.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP219192\">lamivudine with tenofovir disoproxil and doravirine</xref> dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Rifabutin   moderately   decreases   the exposure to   doravirine .  Manufacturer advises adjust  doravirine  or  lamivudine with tenofovir disoproxil and doravirine  dose .    \n\n"
						}
					],
					"hasOrder": "15",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Doravirine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/rifabutin-2#bnf_i1643858010467",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/rifabutin-2#bnf_i1643858010467_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"efavirenz\" outputclass=\"int-drug\">Efavirenz</ph> <ph outputclass=\"int-magnitude\">slightly</ph> <ph outputclass=\"int-effect\">decreases</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"rifabutin\" outputclass=\"int-heading-drug\">rifabutin</ph>. <ph outputclass=\"int-action\">Manufacturer advises adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Efavirenz   slightly   decreases   the exposure to   rifabutin .  Manufacturer advises adjust dose .    \n\n"
						}
					],
					"hasOrder": "16",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Efavirenz</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/rifabutin-2#bnf_i1643858010468",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/rifabutin-2#bnf_i1643858010468_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"rifabutin\" outputclass=\"int-heading-drug\">Rifabutin</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"elexacaftor\" outputclass=\"int-drug\">elexacaftor</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Rifabutin   is predicted to   decrease   the exposure to   elexacaftor .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "17",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Elexacaftor</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/rifabutin-2#bnf_i1643858010469",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/rifabutin-2#bnf_i1643858010469_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"erythromycin\" outputclass=\"int-drug\">Erythromycin</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the concentration of</ph> <ph otherprops=\"rifabutin\" outputclass=\"int-heading-drug\">rifabutin</ph> and <ph otherprops=\"rifabutin\" outputclass=\"int-heading-drug\">rifabutin</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the concentration of</ph> <ph otherprops=\"erythromycin\" outputclass=\"int-drug\">erythromycin</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor and adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Erythromycin   is predicted to   increase   the concentration of   rifabutin  and  rifabutin   is predicted to   decrease   the concentration of   erythromycin .  Manufacturer advises monitor and adjust dose .    \n\n"
						}
					],
					"hasOrder": "18",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Erythromycin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/rifabutin-2#bnf_i1643858010470",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/rifabutin-2#bnf_i1643858010470_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"rifabutin\" outputclass=\"int-heading-drug\">Rifabutin</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the efficacy of</ph> <ph otherprops=\"estradiol\" outputclass=\"int-drug\">estradiol</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Rifabutin   is predicted to   decrease   the efficacy of   estradiol .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "19",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Estradiol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/rifabutin-2#bnf_i1643858010471",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/rifabutin-2#bnf_i1643858010471_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"rifabutin\" outputclass=\"int-heading-drug\">Rifabutin</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the efficacy of</ph> <ph otherprops=\"etonogestrel\" outputclass=\"int-drug\">etonogestrel</ph>. <ph outputclass=\"int-action\">For FSRH guidance, see <xref format=\"dita\" href=\"treatment-summary/contraceptives-interactions.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP92512\">Contraceptives, interactions</xref></ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Rifabutin   is predicted to   decrease   the efficacy of   etonogestrel .  For FSRH guidance, see  Contraceptives, interactions .    \n\n"
						}
					],
					"hasOrder": "20",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Etonogestrel</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/rifabutin-2#bnf_i1643858010472",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/rifabutin-2#bnf_i1643858010472_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"rifabutin\" outputclass=\"int-heading-drug\">Rifabutin</ph> <ph outputclass=\"int-effect\">decreases</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"etravirine\" outputclass=\"int-drug\">etravirine</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Rifabutin   decreases   the exposure to   etravirine .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "21",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Etravirine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/rifabutin-2#bnf_i1643858010473",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/rifabutin-2#bnf_i1643858010473_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"fluconazole\" outputclass=\"int-drug\">Fluconazole</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of uveitis when given with</ph> <ph otherprops=\"rifabutin\" outputclass=\"int-heading-drug\">rifabutin</ph>. <ph outputclass=\"int-action\">Manufacturer advises adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Fluconazole   increases   the risk of uveitis when given with   rifabutin .  Manufacturer advises adjust dose .    \n\n"
						}
					],
					"hasOrder": "22",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fluconazole</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/rifabutin-2#bnf_i1643858010474",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/rifabutin-2#bnf_i1643858010474_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"fosamprenavir\" outputclass=\"int-drug\">Fosamprenavir</ph> <ph outputclass=\"int-substanceQualifier\">boosted with ritonavir</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"rifabutin\" outputclass=\"int-heading-drug\">rifabutin</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor and adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Fosamprenavir   boosted with ritonavir   increases   the exposure to   rifabutin .  Manufacturer advises monitor and adjust dose .    \n\n"
						}
					],
					"hasOrder": "23",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fosamprenavir</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/rifabutin-2#bnf_i1643858010475",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/rifabutin-2#bnf_i1643858010475_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"rifabutin\" outputclass=\"int-heading-drug\">Rifabutin</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the effects of</ph> <ph otherprops=\"hormone replacement therapy\" outputclass=\"int-drug\">hormone replacement therapy</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Anecdotal",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Rifabutin   is predicted to   decrease   the effects of   hormone replacement therapy .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "24",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Hormone replacement therapy</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/rifabutin-2#bnf_i1643858010476",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/rifabutin-2#bnf_i1643858010476_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"rifabutin\" outputclass=\"int-heading-drug\">Rifabutin</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"isavuconazole\" outputclass=\"int-drug\">isavuconazole</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Rifabutin   is predicted to   decrease   the exposure to   isavuconazole .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "25",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Isavuconazole</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/rifabutin-2#bnf_i1643858010477",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/rifabutin-2#bnf_i1643858010477_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"itraconazole\" outputclass=\"int-drug\">Itraconazole</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the concentration of</ph> <ph otherprops=\"rifabutin\" outputclass=\"int-heading-drug\">rifabutin</ph> and <ph otherprops=\"rifabutin\" outputclass=\"int-heading-drug\">rifabutin</ph> <ph outputclass=\"int-effect\">decreases</ph> <ph outputclass=\"int-parameter\">the concentration of</ph> <ph otherprops=\"itraconazole\" outputclass=\"int-drug\">itraconazole</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Itraconazole   increases   the concentration of   rifabutin  and  rifabutin   decreases   the concentration of   itraconazole .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "26",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Itraconazole</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/rifabutin-2#bnf_i1643858010478",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/rifabutin-2#bnf_i1643858010478_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"ketoconazole\" outputclass=\"int-drug\">Ketoconazole</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the concentration of</ph> <ph otherprops=\"rifabutin\" outputclass=\"int-heading-drug\">rifabutin</ph> and <ph otherprops=\"rifabutin\" outputclass=\"int-heading-drug\">rifabutin</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the concentration of</ph> <ph otherprops=\"ketoconazole\" outputclass=\"int-drug\">ketoconazole</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Ketoconazole   is predicted to   increase   the concentration of   rifabutin  and  rifabutin   is predicted to   decrease   the concentration of   ketoconazole .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "27",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ketoconazole</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/rifabutin-2#bnf_i1643858010479",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/rifabutin-2#bnf_i1643858010479_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"rifabutin\" outputclass=\"int-heading-drug\">Rifabutin</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"ledipasvir\" outputclass=\"int-drug\">ledipasvir</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Rifabutin   is predicted to   decrease   the exposure to   ledipasvir .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "28",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ledipasvir</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/rifabutin-2#bnf_i1643858010480",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/rifabutin-2#bnf_i1643858010480_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"rifabutin\" outputclass=\"int-heading-drug\">Rifabutin</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the concentration of</ph> <ph otherprops=\"letermovir\" outputclass=\"int-drug\">letermovir</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Rifabutin   is predicted to   decrease   the concentration of   letermovir .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "29",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Letermovir</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/rifabutin-2#bnf_i1643858010481",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/rifabutin-2#bnf_i1643858010481_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"rifabutin\" outputclass=\"int-heading-drug\">Rifabutin</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the efficacy of</ph> <ph otherprops=\"levonorgestrel\" outputclass=\"int-drug\">levonorgestrel</ph>. <ph outputclass=\"int-action\">For FSRH guidance, see <xref format=\"dita\" href=\"treatment-summary/contraceptives-interactions.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP92512\">Contraceptives, interactions</xref></ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Rifabutin   is predicted to   decrease   the efficacy of   levonorgestrel .  For FSRH guidance, see  Contraceptives, interactions .    \n\n"
						}
					],
					"hasOrder": "30",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Levonorgestrel</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/rifabutin-2#bnf_i1643858010482",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/rifabutin-2#bnf_i1643858010482_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"lopinavir\" outputclass=\"int-drug\">Lopinavir</ph> <ph outputclass=\"int-substanceQualifier\">boosted with ritonavir</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"rifabutin\" outputclass=\"int-heading-drug\">rifabutin</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor and adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Lopinavir   boosted with ritonavir   increases   the exposure to   rifabutin .  Manufacturer advises monitor and adjust dose .    \n\n"
						}
					],
					"hasOrder": "31",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Lopinavir</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/rifabutin-2#bnf_i1643858010483",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/rifabutin-2#bnf_i1643858010483_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"lumacaftor\" outputclass=\"int-drug\">Lumacaftor</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"rifabutin\" outputclass=\"int-heading-drug\">rifabutin</ph>. <ph outputclass=\"int-action\">Manufacturer advises adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Lumacaftor   is predicted to   decrease   the exposure to   rifabutin .  Manufacturer advises adjust dose .    \n\n"
						}
					],
					"hasOrder": "32",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Lumacaftor</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/rifabutin-2#bnf_i1643858010484",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/rifabutin-2#bnf_i1643858010484_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"miconazole\" outputclass=\"int-drug\">Miconazole</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the concentration of</ph> <ph otherprops=\"rifabutin\" outputclass=\"int-heading-drug\">rifabutin</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution and adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Miconazole   is predicted to   increase   the concentration of   rifabutin .  Manufacturer advises use with caution and adjust dose .    \n\n"
						}
					],
					"hasOrder": "33",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Miconazole</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/rifabutin-2#bnf_i1643858010485",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/rifabutin-2#bnf_i1643858010485_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"rifabutin\" outputclass=\"int-heading-drug\">Rifabutin</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the efficacy of</ph> <ph otherprops=\"norethisterone\" outputclass=\"int-drug\">norethisterone</ph>. <ph outputclass=\"int-action\">For FSRH guidance, see <xref format=\"dita\" href=\"treatment-summary/contraceptives-interactions.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP92512\">Contraceptives, interactions</xref></ph>.  </p>"
							},
							"hasEvidence": "Anecdotal",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Rifabutin   is predicted to   decrease   the efficacy of   norethisterone .  For FSRH guidance, see  Contraceptives, interactions .    \n\n"
						}
					],
					"hasOrder": "34",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Norethisterone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/rifabutin-2#bnf_i1643858010486",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/rifabutin-2#bnf_i1643858010486_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"posaconazole\" outputclass=\"int-drug\">Posaconazole</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the concentration of</ph> <ph otherprops=\"rifabutin\" outputclass=\"int-heading-drug\">rifabutin</ph> and <ph otherprops=\"rifabutin\" outputclass=\"int-heading-drug\">rifabutin</ph> <ph outputclass=\"int-effect\">decreases</ph> <ph outputclass=\"int-parameter\">the concentration of</ph> <ph otherprops=\"posaconazole\" outputclass=\"int-drug\">posaconazole</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Posaconazole   increases   the concentration of   rifabutin  and  rifabutin   decreases   the concentration of   posaconazole .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "35",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Posaconazole</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/rifabutin-2#bnf_i1643858010487",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/rifabutin-2#bnf_i1643858010487_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"rifabutin\" outputclass=\"int-heading-drug\">Rifabutin</ph> <ph outputclass=\"int-magnitude\">modestly</ph> <ph outputclass=\"int-effect\">decreases</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"rilpivirine\" outputclass=\"int-drug\">rilpivirine</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid or adjust dose—consult product literature</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Rifabutin   modestly   decreases   the exposure to   rilpivirine .  Manufacturer advises avoid or adjust dose—consult product literature .    \n\n"
						}
					],
					"hasOrder": "36",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Rilpivirine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/rifabutin-2#bnf_i1643858010488",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/rifabutin-2#bnf_i1643858010488_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"ritonavir\" outputclass=\"int-drug\">Ritonavir</ph> <ph outputclass=\"int-magnitude\">markedly</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"rifabutin\" outputclass=\"int-heading-drug\">rifabutin</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid or adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Ritonavir   markedly   increases   the exposure to   rifabutin .  Manufacturer advises avoid or adjust dose .    \n\n"
						}
					],
					"hasOrder": "37",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ritonavir</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/rifabutin-2#bnf_i1643858010489",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/rifabutin-2#bnf_i1643858010489_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"rifabutin\" outputclass=\"int-heading-drug\">Rifabutin</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"tenofovir alafenamide\" outputclass=\"int-drug\">tenofovir alafenamide</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Rifabutin   is predicted to   decrease   the exposure to   tenofovir alafenamide .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "38",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tenofovir alafenamide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/rifabutin-2#bnf_i1643858010490",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/rifabutin-2#bnf_i1643858010490_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"rifabutin\" outputclass=\"int-heading-drug\">Rifabutin</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"tezacaftor\" outputclass=\"int-drug\">tezacaftor</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Rifabutin   is predicted to   decrease   the exposure to   tezacaftor .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "39",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tezacaftor</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/rifabutin-2#bnf_i1643858010491",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/rifabutin-2#bnf_i1643858010491_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"tipranavir\" outputclass=\"int-drug\">Tipranavir</ph> <ph outputclass=\"int-substanceQualifier\">boosted with ritonavir</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"rifabutin\" outputclass=\"int-heading-drug\">rifabutin</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor and adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Tipranavir   boosted with ritonavir   increases   the exposure to   rifabutin .  Manufacturer advises monitor and adjust dose .    \n\n"
						}
					],
					"hasOrder": "40",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tipranavir</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/rifabutin-2#bnf_i1643858010492",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/rifabutin-2#bnf_i1643858010492_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"rifabutin\" outputclass=\"int-heading-drug\">Rifabutin</ph> <ph outputclass=\"int-effect\">decreases</ph> <ph outputclass=\"int-parameter\">the efficacy of</ph> <ph otherprops=\"ulipristal\" outputclass=\"int-drug\">ulipristal</ph>. <ph outputclass=\"int-action\">For FSRH guidance, see <xref format=\"dita\" href=\"treatment-summary/contraceptives-interactions.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP92512\">Contraceptives, interactions</xref></ph>.  </p>"
							},
							"hasEvidence": "Anecdotal",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Rifabutin   decreases   the efficacy of   ulipristal .  For FSRH guidance, see  Contraceptives, interactions .    \n\n"
						}
					],
					"hasOrder": "41",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ulipristal</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/rifabutin-2#bnf_i1643858010493",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/rifabutin-2#bnf_i1643858010493_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"rifabutin\" outputclass=\"int-heading-drug\">Rifabutin</ph> <ph outputclass=\"int-effect\">decreases</ph> <ph outputclass=\"int-parameter\">the concentration of</ph> <ph otherprops=\"voriconazole\" outputclass=\"int-drug\">voriconazole</ph> and <ph otherprops=\"voriconazole\" outputclass=\"int-drug\">voriconazole</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the concentration of</ph> <ph otherprops=\"rifabutin\" outputclass=\"int-heading-drug\">rifabutin</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid or adjust <ph otherprops=\"voriconazole\" outputclass=\"int-drug\"><xref format=\"dita\" href=\"drug/voriconazole.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP3709\">voriconazole</xref></ph> dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Rifabutin   decreases   the concentration of   voriconazole  and  voriconazole   increases   the concentration of   rifabutin .  Manufacturer advises avoid or adjust  voriconazole  dose .    \n\n"
						}
					],
					"hasOrder": "42",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Voriconazole</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/rifabutin-2#bnf_i1643858010494",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/rifabutin-2#bnf_i1643858010494_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"rifabutin\" outputclass=\"int-heading-drug\">Rifabutin</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the concentration of</ph> <ph otherprops=\"voxilaprevir\" outputclass=\"int-drug\">voxilaprevir</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Rifabutin   is predicted to   decrease   the concentration of   voxilaprevir .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "43",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Voxilaprevir</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/rifabutin-2#bnf_i1643858010495",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/rifabutin-2#bnf_i1643858010495_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"rifabutin\" outputclass=\"int-heading-drug\">Rifabutin</ph> <ph outputclass=\"int-effectQualifier\">might</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the anticoagulant effect of</ph> <ph otherprops=\"warfarin\" outputclass=\"int-drug\">warfarin</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Rifabutin   might   decrease   the anticoagulant effect of   warfarin .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "44",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Warfarin</title>"
					}
				}
			],
			"hasSearchLabel": " Rifabutin  | Interactions",
			"hasSearchLink": {
				"@id": "http://bnf.nice.org.uk/interaction/rifabutin-2.html"
			},
			"hasTitle": {
				"@type": "rdf:XMLLiteral",
				"@value": "<title> Rifabutin </title>"
			},
			"rdfs:label": "rifabutin"
		}
	]
}